Crotedumab

Crotedumab (REGN1193) (INN) is a humanized monoclonal antibody designed for the treatment of diabetes.[1][2]

Crotedumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	GCGR
Clinical data
Other names	REGN1193
ATC code	none
Identifiers
CAS Number	1452387-69-7
ChemSpider	none
UNII	4JQ68PW6XF
KEGG	D11230
Chemical and physical data
Formula	C₆₅₁₈H₁₀₀₄₄N₁₇₃₂O₂₀₅₂S₄₆
Molar mass	146976.88 g·mol⁻¹

This drug was developed by Regeneron Pharmaceuticals.

References

Statement On A Nonproprietary Name Adopted By The USAN Council - Crotedumab, American Medical Association.
World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF). WHO Drug Information. 29 (4).

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.